STAA on Nasdaq
STAAR SURGICAL CO
STAAR Surgical Company designs, develops, manufactures, and sells implantable lenses for the eye and accessory delivery systems used to deliver the lenses into the eye.5 From its latest annual report
Price unavailable
Last updated Oct 19, 2026.
Overview
Compare with RxSight, Inc., Warby Parker or National Vision Holdings, Inc., or pick any stock.
- TickerSTAA on Nasdaq2
- IndustryOphthalmic Goods2
- HeadquartersMonrovia, United States2
- Incorporated inDE4
- Business address1911 Walker Ave, Monrovia, Ca 910164
- Filer categoryLarge accelerated filer4
- Legal formCorporation2
- LEI5299006LRHI7OJ8BY3082
- StatusActive2
- LEI statusLapsed (not renewed)2
- Registered addressc/o Corporation Service Company, 251 Little Service Company, 19808 Wilmington, United States2
- Registered withDivision of Corporations, Department of State, 20874872
See how the biggest companies compare on our leaderboards
STAAR Surgical Company designs, develops, manufactures, and sells implantable lenses for the eye and accessory delivery systems used to deliver the lenses into the eye. We are the leading manufacturer of phakic implantable lenses used worldwide in corrective or “refractive” surgery. We have been dedicated solely to ophthalmic surgery for over 40 years. Our goal is to position our refractive lenses throughout the world as primary and premium solutions for patients seeking visual freedom from wearing eyeglasses or contact lenses while achieving excellent visual acuity through refractive vision correction. Unless the context indicates otherwise, “we,” “us,” the “Company,” and “STAAR” refer to STAAR Surgical Company and its consolidated subsidiaries.5 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2026
Where the money goes
Where each dollar of revenue went, fiscal 2026
- Cost of revenue15¢$57.0M
- Research and development11¢$40.1M
- Selling, general and admin73¢$274.1M
- Income tax0¢$1.8M
Out of $239.4M in revenue.3 The company lost money this year.
Financial statements
| Fiscal year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $20.9M6 | $230.5M7 | $239.4M3 | $322.4M3 | $313.9M3 | $239.4M3 | ||
| Cost of revenue | $38.2M8 | $51.8M7 | $61.0M9 | $69.8M3 | $74.3M3 | $57.0M3 | ||
| Gross profit | $112.0M8 | $178.6M7 | $223.4M9 | $252.7M3 | $239.6M3 | $182.4M3 | ||
| Research and development | $25.3M8 | $33.9M7 | $36.0M9 | $40.5M3 | $45.3M3 | $40.1M3 | ||
| Selling, general and admin | $100.1M8 | $145.3M7 | $179.6M9 | $224.6M3 | $252.2M3 | $274.1M3 | ||
| Operating income | $11.9M8 | $33.3M7 | $43.8M9 | $28.1M3 | -$12.6M3 | -$91.7M3 | ||
| Interest | ||||||||
| Income before tax | $31.3M7 | $45.6M9 | $33.7M3 | -$9.1M3 | -$82.3M3 | |||
| Income tax | -$1.0M8 | $3.8M7 | $5.9M9 | $12.3M3 | $11.2M3 | -$1.8M3 | ||
| Net income | $14.0M8 | $27.5M7 | $39.7M9 | $21.3M3 | -$20.2M3 | -$80.4M3 | ||
| Earnings per share | $0.328 | $0.587 | $0.839 | $0.443 | -$0.413 | -$1.623 | ||
| Earnings per share (diluted) | $0.308 | $0.567 | $0.809 | $0.433 | -$0.413 | -$1.623 | ||
| Shares (weighted, basic) | 47.2M shares7 | 48.0M shares9 | 48.5M shares3 | 49.1M shares3 | 49.6M shares3 | |||
| Shares (weighted, diluted) | 49.5M shares7 | 49.4M shares9 | 49.4M shares3 | 49.1M shares3 | 49.6M shares3 |
| Fiscal year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash | $120.0M6 | $199.7M13 | $86.5M7 | $183.0M9 | $144.2M3 | $153.2M3 | ||
| Receivables | $43.5M13 | $62.4M7 | $94.7M9 | $77.9M3 | $50.1M3 | |||
| Current assets | $174.7M6 | $271.4M13 | $311.7M7 | $365.3M9 | $367.9M3 | $311.5M3 | ||
| Property, plant and equipment | $35.9M13 | $50.9M7 | $66.8M9 | $84.9M3 | $73.3M3 | |||
| Goodwill | $1.8M13 | $1.8M7 | $1.8M9 | $1.8M3 | $1.8M3 | |||
| Intangible assets | $218.0K13 | $173.0K7 | ||||||
| Total assets | $207.5M6 | $345.8M13 | $418.8M7 | $488.7M9 | $509.5M3 | $451.7M3 | ||
| Accounts payable | $8.7M13 | $11.6M7 | $13.6M9 | $16.7M3 | $11.6M3 | |||
| Current liabilities | $34.5M6 | $48.8M13 | $51.7M7 | $65.0M9 | $70.3M3 | $68.5M3 | ||
| Total liabilities | $47.6M6 | $87.2M13 | $82.7M7 | $102.7M9 | $112.2M3 | $107.5M3 | ||
| Retained earnings | -$111.4M13 | -$68.7M7 | -$47.4M9 | -$67.6M3 | -$148.0M3 | |||
| Shareholders’ equity | $159.9M13 | $261.6M9 | $336.1M3 | $386.0M3 | $397.3M3 | $344.2M3 | ||
| Shares outstanding | 44.2M shares14 | 45.0M shares15 | 47.7M shares13 | 48.2M shares7 | 48.8M shares9 | 49.3M shares3 | 49.3M shares9 | 49.5M shares3 |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
| Fiscal year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | $25.8M8 | $44.0M7 | $35.7M9 | $14.6M3 | $15.7M3 | -$34.2M3 | ||
| Stock-based compensation | $14.6M7 | $20.4M9 | $23.5M3 | $27.2M3 | $30.6M3 | |||
| Capital spending | $10.1M8 | $13.6M7 | $18.1M9 | $18.2M3 | $23.4M3 | $5.8M3 | ||
| Free cash flow | $15.7M | $30.3M | $17.6M | -$3.6M | -$7.7M | -$40.0M | ||
| Cash from investing | -$13.6M7 | -$156.4M9 | $74.3M3 | -$59.2M3 | $46.3M3 | |||
| Share buybacks | $6.5M3 | |||||||
| Cash from financing | $17.8M7 | $8.3M9 | $7.4M3 | $5.7M3 | -$4.6M3 |
Leadership
Who has led STAAR SURGICAL CO, and when. Pick a name to see everywhere that person has worked.
Chief executive
President
Chief financial officer
Chief operating officer
- Chief executive officerDeborah J. Andrews Feb 4, 2026 to now16
- Chief executive officerWarren Foust Feb 4, 2026 to now17
- Chief executive officerStephen C. Farrell Feb 28, 2025 to Feb 4, 202618
- Chief executive officerThomas G. Frinzi Jan 4, 2023 to Jan 6, 202519
- Chief executive officerCaren L. Mason Mar 4, 2015 to Jun 6, 202220
- Chief executive officerBarry G. Caldwell Jan 10, 2008 to Nov 14, 201221
- PresidentStephen C. Farrell Feb 28, 2025 to Mar 18, 202518
- PresidentWarren Foust Mar 18, 2025 to now22
- PresidentThomas G. Frinzi Jan 4, 2023 to Jan 6, 202519
- PresidentHans-Martin Blickensdoerfer May 1, 2015 to May 1, 201523
- PresidentCaren L. Mason Aug 25, 2015 to Jun 6, 202224
- PresidentIsamu Kamijo Apr 12, 2010 to Dec 13, 201025
- PresidentDonald J. Todd Aug 18, 2010 to Jun 7, 201226
- PresidentBarry G. Caldwell Jan 10, 2008 to Nov 14, 201221
- Chief financial officerStephen P. Brown Feb 18, 2016 to Apr 28, 201727
- Chief financial officerDeborah J. Andrews Feb 14, 2006 to Feb 18, 201628
- Chief operating officerWarren Foust Mar 29, 2023 to now29
Board members and other officers (47)
- Chief Clinical, Regulatory,Magda Michna Mar 29, 2023 to now30
- Senior VP,OperationsRobert Studholme Jul 5, 2022 to Mar 10, 202331
- Sr. VP, Global OperationsGraydon C. Hansen Jul 10, 2019 to May 12, 202132
- VP, Global Clinical, MedicalJon K. Hayashida Jul 10, 2019 to May 12, 202133
- Chief Medical OfficerScott D. Barnes Jul 10, 2019 to Mar 21, 202334
- V.P., Research & DevelopmentKeith Holliday Jul 1, 2016 to Mar 21, 202335
- VP, Global MarketingJames E. Francese Mar 7, 2013 to Mar 21, 202336
- Vice PresidentDeborah J. Andrews Sep 11, 2013 to Sep 11, 201337
- Vice President & Chief FinanciStephen P. Brown Sep 11, 2013 to Apr 10, 201538
- Vice President, Switzerland OpPhilippe Subrin Aug 19, 2011 to Mar 7, 201339
- V.P. Sales for N. AmericaDonald L. Fagen Jan 22, 2010 to Mar 6, 201240
- VP, International MarketingHans-Martin Blickensdoerfer Apr 12, 2010 to Mar 8, 202241
- Global VP, Human ResourcesWilliam Walter Goodmen Aug 18, 2010 to Aug 22, 201242
- VP, R&D and Clinical AffairsCraig Felberg Jul 11, 2007 to Jun 7, 201243
- Vice President, MarketingRobin Hughes Jul 11, 2007 to Apr 10, 201544
- Vice President - R & DThomas R. Paul Feb 14, 2006 to Feb 14, 200645
- Vice President, OperationsPaul Hambrick Mar 2, 2006 to Feb 19, 200846
- Sr. VP Sales and MarketingNicholas T. Curtis Apr 6, 2006 to May 19, 200847
- Vice President, QA/RARobert Kenneth Lally Nov 3, 2006 to Apr 4, 200748
- Board memberRichard T. Lebuhn Jan 23, 2026 to now49
- Board memberChristopher Min Fang Wang Feb 10, 2026 to now50
- Board memberNeal C. Bradsher Mar 10, 2026 to now51
- Board memberArthur C. Butcher Mar 12, 2024 to now52
- Board memberWei Jiang Mar 12, 2024 to now53
- Board memberLilian Yansheng Zhou Dec 4, 2023 to now54
- Board memberAimee S. Weisner Jun 17, 2022 to Jun 24, 202455
- Board memberElizabeth Yeu Lin Jan 26, 2021 to now56
- Board memberK. Peony Yu Jan 26, 2021 to Jun 16, 202357
- Board memberGilbert H. Kliman Jun 3, 2020 to Dec 5, 202358
- Board memberThomas G. Frinzi Jun 3, 2020 to Jan 6, 202559
- Board memberStephen C. Farrell Jan 5, 2016 to now60
- Board memberWilliam P. Wall Sep 2, 2015 to Dec 13, 201961
- Board memberKathryn Tunstall Feb 3, 2014 to Jun 11, 201462
- Board memberCaren L. Mason Jun 11, 2014 to Jun 6, 202263
- Board memberLou Silverman Sep 16, 2014 to now64
- Board memberCharles P. Slacik Sep 17, 2012 to Jul 10, 201565
- Board memberMark B. Logan Nov 17, 2010 to Jul 10, 201566
- Board memberRichard A. Meier Jul 1, 2009 to May 23, 201667
- Board memberJohn C. Moore Feb 7, 2008 to Dec 4, 202068
- Board memberDavid L. Schlotterbeck May 23, 2007 to May 23, 200769
- Board memberBarry G. Caldwell May 24, 2007 to Jun 11, 201470
- Board memberVolker D. Anhaeusser Feb 14, 2006 to Feb 14, 200671
- Board memberDavid R. Morrison May 2, 2006 to Dec 2, 201172
- Board memberDonald Duffy May 22, 2006 to May 15, 201273
- General counselNathaniel Sisitsky Dec 12, 2023 to now74
- General counselSamuel J. Gesten Apr 10, 2012 to Mar 21, 202375
- General counselCharles S. Kaufman Apr 4, 2007 to Aug 26, 201176
Former names
- STAAR SURGICAL COMPANYAug 10, 1995 to Aug 17, 20044
Timeline
- Feb 4, 2026New chief executive Deborah J. Andrews becomes CEO16
- Feb 4, 2026New chief executive Warren Foust becomes CEO17
- Feb 28, 2025New chief executive Stephen C. Farrell becomes CEO18
- Jan 4, 2023New chief executive Thomas G. Frinzi becomes CEO19
- Mar 4, 2015New chief executive Caren L. Mason becomes CEO20
- Jan 10, 2008New chief executive Barry G. Caldwell becomes CEO21
Filings
433 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 86 major events, 174 insider forms, 52 large holders, 101 other. The latest 20:
- Oct 5, 20268-K/A EDGAR
- Sep 10, 20268-K EDGAR
- Aug 18, 20264 EDGAR
- Aug 18, 20264 EDGAR
- Aug 18, 20264 EDGAR
- Aug 14, 2026SCHEDULE 13G/A EDGAR
- Aug 12, 202610-Q EDGAR
- Aug 12, 20268-K EDGAR
- Aug 6, 20268-K EDGAR
- Aug 4, 20264 EDGAR
- Aug 4, 20264 EDGAR
- Jun 24, 2026S-8 EDGAR
- Jun 23, 20264 OWNERSHIP DOCUMENT EDGAR
- Jun 22, 20264 EDGAR
- Jun 22, 20264 EDGAR
- Jun 22, 20264 EDGAR
- Jun 22, 20264 EDGAR
- Jun 22, 20264 EDGAR
- Jun 22, 20264 EDGAR
- Jun 22, 20268-K EDGAR
The 433 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
83 open-market trades by officers, directors and large owners since October 2021: 70 buys and 13 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Mar 13, 2026 | BROADWOOD CAPITAL INC10% owner | Buy | 316,017 | $18.62 | $5.9M | Form 4 |
| Mar 12, 2026 | BROADWOOD CAPITAL INC10% owner | Buy | 299,432 | $18.12 | $5.4M | Form 4 |
| Mar 11, 2026 | BROADWOOD CAPITAL INC10% owner | Buy | 54,764 | $17.52 | $959.5K | Form 4 |
| Jan 9, 2026 | Bradsher Neal CDirector | Buy | 27,485 | $22.05 | $606.0K | Form 4 |
| Jan 8, 2026 | Bradsher Neal CDirector | Buy | 3,240 | $21.94 | $71.1K | Form 4 |
| Jan 7, 2026 | Bradsher Neal CDirector | Buy | 66,467 | $22.00 | $1.5M | Form 4 |
| Jan 6, 2026 | Bradsher Neal CDirector | Buy | 336,946 | $21.62 | $7.3M | Form 4 |
| Nov 21, 2025 | Bradsher Neal CDirector | Buy | 797,486 | $27.86 | $22.2M | Form 4 |
| Nov 20, 2025 | Bradsher Neal CDirector | Buy | 393,382 | $27.14 | $10.7M | Form 4 |
| Nov 19, 2025 | Bradsher Neal CDirector | Buy | 309,132 | $26.42 | $8.2M | Form 4 |
| Apr 10, 2025 | Bradsher Neal CDirector | Buy | 900 | $15.18 | $13.7K | Form 4 |
| Apr 9, 2025 | Bradsher Neal CDirector | Buy | 8,200 | $15.08 | $123.7K | Form 4 |
| Apr 8, 2025 | Bradsher Neal CDirector | Buy | 178,127 | $15.32 | $2.7M | Form 4 |
| Apr 7, 2025 | BROADWOOD PARTNERS, L.P.Director | Buy | 138,054 | $15.61 | $2.2M | Form 4 |
| Apr 4, 2025 | BROADWOOD PARTNERS, L.P.Director | Buy | 497,631 | $15.91 | $7.9M | Form 4 |
| Apr 3, 2025 | BROADWOOD PARTNERS, L.P.Director | Buy | 209,535 | $16.97 | $3.6M | Form 4 |
| Apr 2, 2025 | BROADWOOD PARTNERS, L.P.Director | Buy | 31,780 | $17.43 | $553.9K | Form 4 |
| Mar 31, 2025 | BROADWOOD PARTNERS, L.P.Director | Buy | 22,189 | $17.46 | $387.4K | Form 4 |
| Mar 28, 2025 | Bradsher Neal CDirector | Buy | 8,131 | $17.47 | $142.0K | Form 4 |
| Mar 27, 2025 | Bradsher Neal CDirector | Buy | 3,620 | $17.48 | $63.3K | Form 4 |
All 83 trades can be filtered by person here when JavaScript is on.
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- Madison Avenue Partners, LPSCHEDULE 13G/A, 2 filings Apr 20, 2026 to Aug 14, 202677
- Point72 Asset Management, L.P.SCHEDULE 13G, 1 filing May 12, 202678
- BlackRockSCHEDULE 13G/A, 4 filings Oct 18, 2024 to Apr 24, 202679
- VANGUARD GROUP INCSCHEDULE 13G/A, 5 filings Feb 10, 2022 to Mar 27, 202680
- BROADWOOD PARTNERS, L.P.SCHEDULE 13D/A, 17 filings Oct 1, 2021 to Mar 13, 202681
- Yunqi Capital LtdSCHEDULE 13D/A, 8 filings Sep 22, 2025 to Jan 16, 202682
- ARMISTICE CAPITAL, LLCSCHEDULE 13G/A, 3 filings May 15, 2025 to Nov 14, 202583
- Soleus Capital Master Fund, L.P.SCHEDULE 13G/A, 2 filings Mar 28, 2025 to Nov 7, 202584
- BAILLIE GIFFORD & COSC 13G/A, 4 filings Jan 26, 2022 to Sep 6, 202485
- Palo Alto Investors LPSC 13G/A, 1 filing Feb 14, 202286
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| Broadwood Capital Inc | 16,123,842 | $462.6M | 24.2% | No change |
| BlackRock, Inc. | 6,731,154 | $193.1M | 0.0% | +65,036 |
| Madison Avenue Partners, LP | 4,175,748 | $119.8M | 5.2% | +1,734,070 |
| Yunqi Capital Ltd | 3,257,130 | $93.4M | 74.8% | No change |
| Point72 Asset Management, L.P. | 2,437,446 | $69.9M | 0.1% | +1,614,294 |
| Goldman Sachs Group Inc | 2,150,809 | $61.7M | 0.0% | +1,080,870 |
| Vanguard Portfolio Management LLC | 1,979,573 | $56.8M | 0.0% | −144,016 |
| State Street Corp | 1,769,354 | $50.8M | 0.0% | −63,642 |
| Anatole Investment Management Ltd | 1,651,701 | $47.4M | 8.0% | +50,000 |
| Vanguard Capital Management LLC | 1,552,743 | $44.5M | 0.0% | −137,863 |
| Morgan Stanley | 1,316,119 | $37.8M | 0.0% | −183,237 |
| Geode Capital Management, LLC | 1,076,006 | $30.9M | 0.0% | +59,502 |
| Two Seas Capital LP | 1,064,389 | $30.5M | 1.2% | +27,416 |
| Dimensional Fund Advisors LP | 867,142 | $24.9M | 0.0% | +46,360 |
| American Capital Management Inc | 846,659 | $24.3M | 1.1% | −31,376 |
| AI-Squared Management Ltd | 542,420 | $15.6M | 8.3% | +274,336 |
| Charles Schwab Investment Management Inc | 445,713 | $12.8M | 0.0% | +37,137 |
| Defender Capital, LLC. | 431,187 | $12.4M | 4.0% | −213,355 |
| Northern Trust Corp | 423,112 | $12.1M | 0.0% | +22,894 |
| Norges Bank | 365,200 | $10.5M | 0.0% | New |
| UBS Group AG | 341,183 | $9.8M | 0.0% | +161,254 |
| Renaissance Technologies LLC | 340,400 | $9.8M | 0.0% | +205,200 |
| Defilade Capital Management, L.P. | 322,126 | $9.2M | 1.2% | New |
| Vanguard Fiduciary Trust Co | 322,004 | $9.2M | 0.0% | −66 |
| Principal Financial Group Inc | 241,976 | $6.9M | 0.0% | +1 |
13F reports cover disclosed long positions in U.S. stocks only.
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22SEC EDGARWarren Foust, President
- 23
- 24SEC EDGARCaren L. Mason, President
- 25SEC EDGARIsamu Kamijo, President
- 26SEC EDGARDonald J. Todd, President
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37SEC EDGARDeborah J. Andrews, Vice President
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49SEC EDGARRichard T. Lebuhn, Board member
- 50
- 51SEC EDGARNeal C. Bradsher, Board member
- 52SEC EDGARArthur C. Butcher, Board member
- 53SEC EDGARWei Jiang, Board member
- 54SEC EDGARLilian Yansheng Zhou, Board member
- 55SEC EDGARAimee S. Weisner, Board member
- 56SEC EDGARElizabeth Yeu Lin, Board member
- 57SEC EDGARK. Peony Yu, Board member
- 58SEC EDGARGilbert H. Kliman, Board member
- 59SEC EDGARThomas G. Frinzi, Board member
- 60SEC EDGARStephen C. Farrell, Board member
- 61SEC EDGARWilliam P. Wall, Board member
- 62SEC EDGARKathryn Tunstall, Board member
- 63SEC EDGARCaren L. Mason, Board member
- 64SEC EDGARLou Silverman, Board member
- 65SEC EDGARCharles P. Slacik, Board member
- 66SEC EDGARMark B. Logan, Board member
- 67SEC EDGARRichard A. Meier, Board member
- 68SEC EDGARJohn C. Moore, Board member
- 69SEC EDGARDavid L. Schlotterbeck, Board member
- 70SEC EDGARBarry G. Caldwell, Board member
- 71SEC EDGARVolker D. Anhaeusser, Board member
- 72SEC EDGARDavid R. Morrison, Board member
- 73SEC EDGARDonald Duffy, Board member
- 74SEC EDGARNathaniel Sisitsky, General counsel
- 75SEC EDGARSamuel J. Gesten, General counsel
- 76SEC EDGARCharles S. Kaufman, General counsel
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86